

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

Recombinant Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022]

RRID:AB_3073570

Type: Antibody

Proper Citation

Abcam Cat# ab273073, RRID:AB_3073570

Antibody Information

URL: http://antibodyregistry.org/AB_3073570

Proper Citation: Abcam Cat# ab273073, RRID:AB_3073570

Target Antigen: Spike Glycoprotein S1

Host Organism: Human

Clonality: recombinant monoclonal

Comments: Applications: Indirect ELISA, ELISA

Antibody Name: Recombinant Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022]

Description: This recombinant monoclonal targets Spike Glycoprotein S1

Target Organism: sars-cov-2

Clone ID: CR3022

Antibody ID: AB_3073570

Vendor: Abcam

Catalog Number: ab273073

Record Creation Time: 20231110T031022+0000

Record Last Update: 20260829T074356+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022].

No alerts have been found for Recombinant Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Montamat-Garcia G, et al. (2026) Human primary antibody response to vaccination follows a partially sequential class-switching program with a checkpoint at IGHG2. Cell reports. Medicine, 7(7), 102848.

Voss WN, et al. (2024) Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination. Cell reports. Medicine, 5(8), 101668.